Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $39.00.

A number of analysts have weighed in on ARTV shares. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Wedbush raised their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Finally, HC Wainwright raised their price objective on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th.

Insider Transactions at Artiva Biotherapeutics

In related news, Director Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock in a transaction dated Thursday, June 11th. The stock was purchased at an average cost of $7.91 per share, for a total transaction of $4,339,267.80. Following the completion of the purchase, the director directly owned 16,231,717 shares of the company’s stock, valued at $128,392,881.47. The trade was a 3.50% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Fred Aslan sold 27,116 shares of Artiva Biotherapeutics stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $244,315.16. Following the completion of the sale, the chief executive officer owned 1,535,082 shares of the company’s stock, valued at $13,831,088.82. This represents a 1.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders purchased 8,970,429 shares of company stock valued at $99,150,133 and sold 53,040 shares valued at $477,890. Insiders own 21.40% of the company’s stock.

Institutional Trading of Artiva Biotherapeutics

Large investors have recently made changes to their positions in the stock. Prelude Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the third quarter worth approximately $41,000. Bank of America Corp DE grew its stake in shares of Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of Artiva Biotherapeutics in the first quarter worth approximately $131,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Artiva Biotherapeutics in the fourth quarter worth approximately $91,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Artiva Biotherapeutics in the first quarter worth approximately $139,000.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $8.54 on Wednesday. The firm has a market cap of $211.11 million, a P/E ratio of -2.41 and a beta of 2.40. Artiva Biotherapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $14.53. The firm has a 50-day simple moving average of $8.93 and a two-hundred day simple moving average of $6.16.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, equities research analysts predict that Artiva Biotherapeutics will post -2.45 EPS for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.